PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-12.60%
Both yoy net incomes decline, with VET at -25.24%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
2.83%
Some D&A expansion while VET is negative at -7.50%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
51.72%
Well above VET's 33.19% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
206.67%
SBC growth while VET is negative at -18.06%. John Neff would see competitor possibly controlling share issuance more tightly.
-76.69%
Both reduce yoy usage, with VET at -161.01%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
303.27%
AR growth of 303.27% while VET is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
No Data
No Data available this quarter, please select a different quarter.
-220.33%
Negative yoy AP while VET is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-26.19%
Both reduce yoy usage, with VET at -161.01%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-2933.33%
Negative yoy while VET is 104.37%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-28.42%
Both yoy CFO lines are negative, with VET at -15.60%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
No Data
No Data available this quarter, please select a different quarter.
7200.00%
Acquisition spending well above VET's 99.56%. Michael Burry would suspect heavier integration risk or short-term free cash flow drain vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
750.00%
Growth well above VET's 32.13%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
48.64%
Investing outflow well above VET's 72.53%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
52.31%
Debt repayment similar to VET's 53.53%. Walter Schloss sees parallel liability management or similar free cash flow availability.
No Data
No Data available this quarter, please select a different quarter.
-140.74%
We cut yoy buybacks while VET is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.